NBIX:NGS-Neurocrine Biosciences Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 79.40

Change

0.00 (0.00)%

Market Cap

USD 7.14B

Volume

0.60M

Yahoo Analyst Target

USD 105.36 (32.70%)

STA Analyst Target

USD 94.96 (19.60%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TIG TiGenix

N/A

USD 253.20B
AMGN Amgen Inc.

N/A

USD 114.65B
GILD Gilead Sciences Inc.

N/A

USD 96.09B
CELG Celgene Corporation

N/A

USD 66.91B
BIIB Biogen Inc.

N/A

USD 55.65B
SHPG Shire plc

N/A

USD 49.98B
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD 40.31B
REGN Regeneron Pharmaceuticals Inc.

N/A

USD 33.84B
ALXN Alexion Pharmaceuticals Inc.

N/A

USD 23.97B
NKTR Nektar Therapeutics

N/A

USD 14.59B

ETFs Containing NBIX

FBT First Trust Amex Biotech .. 3.43 % 0.56 %

N/A

USD 1.45B
BBP Virtus LifeSci Biotech Pr.. 3.05 % 0.84 %

N/A

USD 0.03B
FXH First Trust Health Care A.. 2.56 % 0.62 %

N/A

USD 0.95B
FHH:CA First Trust AlphaDEX U.S... 2.56 % 0.78 %

N/A

CAD 7.26M
BTEC Principal Healthcare Inno.. 2.47 % 0.42 %

N/A

USD 0.05B
SCHA Schwab U.S. Small-Cap 0.26 % 0.06 %

N/A

USD 7.28B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.33% 56% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.33% 56% F 59% F
Trailing 12 Months  
Capital Gain 55.38% 72% C- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.38% 72% C- 86% B
Trailing 5 Years  
Capital Gain 560.57% 92% A- 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 560.57% 92% A- 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 64.52% 91% A- 96% A
Dividend Return 64.52% 91% A- 96% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.71% 27% F 9% F
Risk Adjusted Return 81.97% 97% A+ 76% C
Market Capitalization 4.26B 95% A 92% A-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -48.71 96% A 93% A
Price/Book Ratio 20.31 8% F 4% F
Price / Cash Flow Ratio -15.45 94% A 96% A
Price/Free Cash Flow Ratio -68.45 96% A 94% A
Management Effectiveness  
Return on Equity -43.46% 64% D 21% F
Return on Invested Capital -21.83% 78% C+ 25% F
Return on Assets -21.65% 80% B- 24% F
Debt to Equity Ratio 77.00% 22% F 34% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

NBIX:NGS-Neurocrine Biosciences Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 79.40

Change

0.00 (0.00)%

Market Cap

USD 7.14B

Volume

0.60M

Yahoo Analyst Target

USD 105.36 (32.70%)

STA Analyst Target

USD 94.96 (19.60%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-04-21